The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common type of dementia, which has a substantial genetic component. AD affects predominantly older people. Accordingly, the prevalence of dementia has been rising as the population ages. To date, there are no effective interventions that can cure or halt the progression of AD. The only available treatments are the management of certain symptoms and consequences of dementia. The current state-of-the-art medical care for AD comprises three simple principles: prevent the preventable, achieve early diagnosis, and manage the manageable symptoms. This review provides a summary of the current state of knowledge of risk factors for AD, biological diagnostic testing and prospects for treatment. Special emphasis is given to recent advances in genetics of AD and the way genomic data may support prevention, early intervention and development of effective pharmacological treatments. Mutations in the APP, PSEN1, and PSEN2 genes cause early onset AD (EOAD) that follows a Mendelian inheritance pattern. For late onset AD (LOAD), APOE4 was identified as a major risk allele more than two decades ago. Population-based genome-wide association studies (GWAS) of late onset AD have now additionally identified common variants at roughly 30 genetic loci. Furthermore, rare variants (allele frequency <1%) that influence the risk for LOAD have been identified in several genes. These genetic advances have broadened our insights into the biological underpinnings of AD. Moreover, the known genetic risk variants could be used to identify presymptomatic individuals at risk for AD and support diagnostic assessment of symptomatic subjects. Genetic knowledge may also facilitate precision medicine. The goal of precision medicine is to use biological knowledge and other health information to predict individual disease risk, understand disease etiology, identify disease subcategories, improve diagnosis, and provide personalized treatment strategies. We discuss the potential role of genetics in advancing precision medicine for AD along with its ethical challenges. We outline strategies to implement genomics into translational clinical research that will not only improve accuracy of dementia diagnosis, thus enabling more personalized treatment strategies, but may also speed up the discovery of novel drugs and interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“A recent review presented a large body of evidence from over 25 years of research supporting the generalizability of amyloid hypothesis (51).”
BackgroundDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“APOE encodes a lipid carrier Apolipoprotein E (ApoE) that is found both in the periphery and the central nervous system (66).”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“Using a combination of 18-fluoro-deoxyglucose-positron emission tomography (PET), which measures cerebral glucose metabolism, and Pittsburgh compound B (PIB) PET measuring the Aβ deposition along with CSF biomarkers, it was demonstrated that subjects with known Mendelian AD mutations have CSF Aβ changes, brain amyloid…”
MethodEmdin, C. A., Khera, A. V., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2017.17219 · Cited by 3,637
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The potential impact of rare variants in AD is further underscored by rare and low-frequency protective variants such as APOE2 allele (61, 67), APP A673T (48), and PLGC2 P522R (81).”
BackgroundBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“Over many years, definitive diagnosis of AD could only be made by the “gold standard” of postmortem neuropathological examination, using a combination of CERAD score for neuritic plaques containing amyloid beta (Aβ) (16) together with Braak staging of NFT consisting of abnormally hyperphosphorylated tau (17).”
MethodScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Biogen’s immunotherapeutic drug Aducanumab reported positive Phase 1 results on removing brain Aβ plaques and clinical benefits (133).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 15×
“In addition, both bind to the microglial receptor TREM2 and thus may promote uptake of Aβ by microglia (96).”
BackgroundInfluentialCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 15×
“In addition, both bind to the microglial receptor TREM2 and thus may promote uptake of Aβ by microglia (96).”
BackgroundInfluentialBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 5×
“Mutations in the APP, PSEN1, and PSEN2 genes cause early onset Alzheimer’s disease (EOAD) that follows a Mendelian inheritance pattern.”
BackgroundInfluentialA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 13×
“Thus, both modifiable and non-modifiable risk factors have been associated with LOAD risk.”
BackgroundInfluentialAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“This statement holds despite the stunning fact that between 2002 and 2014, more than 400 drug trials for AD have been performed but subsequently failed (129).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 11×
“Thus, in addition to the Mendelian disease presentation of EOAD, a substantial proportion of EOAD cases fall into the category of sporadic and genetically complex disease.”
BackgroundInfluentialHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660 · cited 1×
“Observational studies have suggested that diabetes, mid-life obesity, mid-life hypertension, high cholesterol, and smoking are modifiable risk factors for AD (107).”
BackgroundHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Larson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“A recent example for protective genetic variants fueling new effective therapeutics was the development of PCSK9 inhibitor for hypercholesterolemia (144, 145).”
BackgroundAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 1×
“Most recently, ApoE has been shown to affect tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology in transgenic mice (70).”
BackgroundPhysical Activity, Including Walking, and Cognitive Function in Older Women
Weuve, J. (2004) · JAMA · doi:10.1001/jama.292.12.1454 · Cited by 1,175
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Candidate-gene approaches for studying complex genetic traits: practical considerations
Tabor, H. K., Risch, N. J., & Myers, R. M. (2002) · Nature Reviews Genetics · doi:10.1038/nrg796 · Cited by 1,076
ARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · cited 1×
“In addition, both bind to the microglial receptor TREM2 and thus may promote uptake of Aβ by microglia (96).”
BackgroundTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 2×
“CSF levels of Aβ42, tau, and hyperphosphorylated tau (ptau) as markers for amyloid, neuronal injury, and tangles, respectively, have been the main fluid biomarkers used in AD research (30, 31).”
BackgroundDementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 1×
“In terms of modifiable protective factors, education has been robustly shown to reduce AD risk (108).”
BackgroundCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Walking and Dementia in Physically Capable Elderly Men
Abbott, R. D. (2004) · JAMA · doi:10.1001/jama.292.12.1447 · Cited by 743
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Podewils, L. J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi092 · Cited by 675
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Meta-analysis of modifiable risk factors for Alzheimer's disease
Xu, W., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Zhao, Q.-F., Li, J.-Q., Wang, J., & Yu, J.-T. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-310548 · Cited by 573 · cited 2×
“A recent comprehensive meta-analysis of 93 modifiable risk factors was conducted from 323 retrospective case/control and prospective cohort studies, which were selected after a systematic review of 16,906 publications (110).”
BackgroundAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 1×
“Ongoing drug trials include targeting anti-amyloid, anti-tau, anti-inflammatory, neuroprotection, stem cell therapy, and metabolism (136).”
BackgroundInconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“For example, elevated amyloid deposition is frequently found in cognitively normal subjects (28, 53–55) and CSF level of Aβ and Aβ imaging with PIB–PET do not correlate with cognitive decline (56).”
BackgroundCommon polygenic variation enhances risk prediction for Alzheimer’s disease
Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., Badarinarayan, N., GERAD/PERADES, consortia, I., Morgan, K., et al. (2015) · Brain · doi:10.1093/brain/awv268 · Cited by 414
Goldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371 · cited 1×
“org April 2018 | Volume 5 | Article 108 An example is to study gene–environment interactions (126) and one study have shown that estrogen use may be associated with less cognitive decline among APOE4 negative women (127).”
BackgroundStaging TDP-43 pathology in Alzheimer’s disease
Josephs, K. A., Murray, M. E., Whitwell, J. L., Parisi, J. E., Petrucelli, L., Jack, C. R., Petersen, R. C., & Dickson, D. W. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1211-9 · Cited by 366
The genetic interpretation of area under the ROC curve in genomic profiling
Wray, N. R., Yang, J., Goddard, M. E., & Visscher, P. M. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000864 · Cited by 334 · cited 1×
“However, the efficacy of a genetic predictor is dependent on prevalence and heritability of a disease (104).”
BackgroundDecreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · cited 2×
“Levels of CSF tau and ptau, but not Aβ42, were found to correlate with brain atrophy in AD (33).”
BackgroundLoss-of-function variants in ABCA7 confer risk of Alzheimer's disease
DemGene, Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O. T., Gudjonsson, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3246 · Cited by 324
Cruchaga, C., Chakraverty, S., Mayo, K., Vallania, F. L. M., Mitra, R. D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., Foroud, T. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031039 · Cited by 320
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Physical activity in relation to cognitive decline in elderly men: The FINE Study
van Gelder, B. M., Tijhuis, M. A. R., Kalmijn, S., Giampaoli, S., Nissinen, A., & Kromhout, D. (2004) · Neurology · doi:10.1212/01.wnl.0000147474.29994.35 · Cited by 311
Hippocampal sclerosis and TDP ‐43 pathology in aging and Alzheimer disease
Nag, S., Yu, L., Capuano, A. W., Wilson, R. S., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2015) · Annals of Neurology · doi:10.1002/ana.24388 · Cited by 305
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 1×
“In CSF of AD patients, a decreased level of Aβ42 has been consistently found (32), whereas the concentrations of tau and ptau are increased (31).”
BackgroundSando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261
Kim, M., Suh, J., Romano, D., Truong, M. H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp323 · Cited by 234
Lee, S. H., Harold, D., Nyholt, D. R., ANZGene Consortium, International Endogene Consortium, the Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium, Goddard, M. E., Zondervan, K. T., Williams, J., Montgomery, G. W., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds491 · Cited by 217
Power, M. C., Weuve, J., Gagne, J. J., McQueen, M. B., Viswanathan, A., & Blacker, D. (2011) · Epidemiology · doi:10.1097/ede.0b013e31822708b5 · Cited by 213 · cited 1×
“However, for many modifiable factors, no consistent pattern was found across studies (109).”
BackgroundØstergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001841 · Cited by 203
Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease
Escott-Price, V., Shoai, M., Pither, R., Williams, J., & Hardy, J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.018 · Cited by 183
Ecology of the Aging Human Brain
Sonnen, J. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.157 · Cited by 174 · cited 1×
“It is important to note that AD pathologies were also found in nearly all brain autopsies of cognitively normal individuals above age 80, even among those considered as high-cognitive performers (28, 29).”
BackgroundAlzheimer's Disease Genetics Consortium, Wetzel-Smith, M. K., Hunkapiller, J., Bhangale, T. R., Srinivasan, K., Maloney, J. A., Atwal, J. K., Sa, S. M., B Yaylaoglu, M., Foreman, O., et al. (2014) · Nature Medicine · doi:10.1038/nm.3736 · Cited by 153 · cited 3×
“Other functional categories include regulation of cell cycle (RANBP2), oxidative stress response (MEF2C), and axon guidance (UNC5C).”
BackgroundCuyvers, E., De Roeck, A., Van den Bossche, T., Van Cauwenberghe, C., Bettens, K., Vermeulen, S., Mattheijssens, M., Peeters, K., Engelborghs, S., Vandenbulcke, M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00133-7 · Cited by 152
Crystal, H. A., Dickson, D., Davies, P., Masur, D., Grober, E., & Lipton, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.713 · Cited by 152
Self-citationFluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140 · cited 1×
“Independently, imaging amyloid and tau was shown to identify such at risk subjects (139).”
BackgroundRecommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138
Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans
Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Ertekin‐Taner, N., Evans, D., Foroud, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.010 · Cited by 136
Frieden, C., & Garai, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207022109 · Cited by 133
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex
Sepulcre, J., Grothe, M. J., Sabuncu, M., Chhatwal, J., Schultz, A. P., Hanseeuw, B., El Fakhri, G., Sperling, R., & Johnson, K. A. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0263 · Cited by 73
ABCA7 rare variants and Alzheimer disease risk
Le Guennec, K., Nicolas, G., Quenez, O., Charbonnier, C., Wallon, D., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002627 · Cited by 69
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1701047 · Cited by 55 · cited 1×
“Attempts to reduce Aβ production (130) as well as immunotherapeutic approaches to clear amyloid plaques from the brain did not show efficacy in slowing down or halting the course of AD (131, 132).”
Background
Research works printed but not linked: 67
- Barker, 2002, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank, Alzheimer Dis Assoc Disord, 16, 203, 10.1097/00002093-200210000-00001 · DOI · Paper page
- Prince, 2015, The burden of disease in older people and implications for health policy and practice, Lancet, 385, 549, 10.1016/S0140-6736(14)61347-7 · DOI · Paper page
- Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI · Paper page
- Aronson, 2015, Building the foundation for genomics in precision medicine, Nature, 526, 336, 10.1038/nature15816 · DOI · Paper page
- McGaghie, 2015, Varieties of integrative scholarship: why rules of evidence, criteria, and standards matter, Acad Med, 90, 294, 10.1097/ACM.0000000000000585 · DOI
- Barsh, 2012, Guidelines for genome-wide association studies, PLoS Genet, 8, e1002812, 10.1371/journal.pgen.1002812 · DOI · Paper page
- MacArthur, 2017, The new NHGRI-EBI catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Res, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
- Alzheimer, 1907, Über eine eigenartige Erkrankung der Hirnrinde, Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin, 64, 146
- McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- Walsh, 1990, Survival of outpatients with Alzheimer-type dementia, Ann Intern Med, 113, 429, 10.7326/0003-4819-113-6-429 · DOI · Paper page
- Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
- Sperling, 2011, Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 270, 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- Rosenberg, 2001, Dementia with Lewy bodies and Alzheimer’s disease, Acta Neuropathol, 102, 621, 10.1007/s004010100415 · DOI
- Cholerton, 2016, Precision medicine: clarity for the complexity of dementia, Am J Pathol, 186, 500, 10.1016/j.ajpath.2015.12.001 · DOI
- Schindler, 2015, Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD, Front Neurol, 6, 142, 10.3389/fneur.2015.00142 · DOI
- Zhu, 2015, Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis, Ann Transl Med, 3, 38, 10.3978/j.issn.2305-5839.2015.01.19 · doi:10.3978/j.issn.2305-5839.2015.01.19 · Paper page
- Jarmolowicz, 2015, The patterns of inheritance in early-onset dementia: Alzheimer’s disease and frontotemporal dementia, Am J Alzheimers Dis Other Demen, 30, 299, 10.1177/1533317514545825 · DOI · Paper page
- An, 2016, A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease, Clin Interv Aging, 11, 1817, 10.2147/CIA.S116724 · DOI
- Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease, Nature, 349, 704, 10.1038/349704a0 · DOI · Paper page
- Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease, Nature, 375, 754, 10.1038/375754a0 · DOI · Paper page
- Weggen, 2012, Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease, Alzheimers Res Ther, 4, 9, 10.1186/alzrt107 · DOI · Paper page
- Sun, 2017, Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase, Proc Natl Acad Sci U S A, 114, E476, 10.1073/pnas.1618657114 · DOI · Paper page
- Maloney, 2014, Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein, J Biol Chem, 289, 30990, 10.1074/jbc.M114.589069 · DOI · Paper page
- Klunk, 2004, Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Aizenstein, 2008, Frequent amyloid deposition without significant cognitive impairment among the elderly, Arch Neurol, 65, 1509, 10.1001/archneur.65.11.1509 · DOI · Paper page
- Musiek, 2015, Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’, Nat Neurosci, 18, 800, 10.1038/nn.4018 · DOI · Paper page
- Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc Natl Acad Sci U S A, 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
- Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
- Bickeboller, 1997, Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex, Am J Hum Genet, 60, 439
- Freudenberg-Hua, 2014, Disease variants in genomes of 44 centenarians, Mol Genet Genomic Med, 2, 438, 10.1002/mgg3.86 · DOI · Paper page
- Zhao, 2018, Apolipoprotein E, receptors, and modulation of Alzheimer’s disease, Biol Psychiatry, 83, 347, 10.1016/j.biopsych.2017.03.003 · DOI · Paper page
- Naj, 2010, Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities, PLoS Genet, 6, e1001130, 10.1371/journal.pgen.1001130 · DOI · Paper page
- Ridge, 2016, Assessment of the genetic variance of late-onset Alzheimer’s disease, Neurobiol Aging, 41, 200.e13, 10.1016/j.neurobiolaging.2016.02.024 · DOI · Paper page
- Freudenberg-Hua, 2016, Differential burden of rare protein truncating variants in Alzheimer’s disease patients compared to centenarians, Hum Mol Genet, 25, 3096, 10.1093/hmg/ddw150 · DOI
- Van Der Lee, 2015, PLD3 variants in population studies, Nature, 520, E2, 10.1038/nature14038 · DOI
- Fernandez, 2017, Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer disease, PLoS Genet, 13, e1007045, 10.1371/journal.pgen.1007045 · DOI
- Heilmann, 2015, PLD3 in non-familial Alzheimer’s disease, Nature, 520, E3, 10.1038/nature14039 · DOI
- Hooli, 2015, PLD3 gene variants and Alzheimer’s disease, Nature, 520, E7, 10.1038/nature14040 · DOI
- Lambert, 2015, PLD3 and sporadic Alzheimer’s disease risk, Nature, 520, E1, 10.1038/nature14036 · DOI · Paper page
- Guerreiro, 2013, SnapShot: genetics of Alzheimer’s disease, Cell, 155, 968, 10.1016/j.cell.2013.10.037 · DOI
- Heneka, 2015, Innate immunity in Alzheimer’s disease, Nat Immunol, 16, 229, 10.1038/ni.3102 · DOI · Paper page
- Wang, 2015, TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model, Cell, 160, 1061, 10.1016/j.cell.2015.01.049 · DOI · Paper page
- Ma, 2016, Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer’s disease brains, Mol Neurodegener, 11, 72, 10.1186/s13024-016-0137-9 · DOI · Paper page
- Warde-Farley, 2010, The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function, Nucleic Acids Res, 38, W214, 10.1093/nar/gkq537 · DOI · Paper page
- Li, 2015, Principles for the organization of gene-sets, Comput Biol Chem, 59, 139, 10.1016/j.compbiolchem.2015.04.005 · DOI
- Purcell, 2009, Common polygenic variation contributes to risk of schizophrenia and bipolar disorder, Nature, 460, 748, 10.1038/nature08185 · DOI · Paper page
- Wray, 2013, Pitfalls of predicting complex traits from SNPs, Nat Rev Genet, 14, 507, 10.1038/nrg3457 · DOI · Paper page
- Lautenschlager, 2008, Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial, JAMA, 300, 1027, 10.1001/jama.300.9.1027 · DOI · Paper page
- Zhou, 2017, Association between exercise and the risk of dementia: results from a nationwide longitudinal study in China, BMJ Open, 7, e017497, 10.1136/bmjopen-2017-017497 · DOI · Paper page
- Barreto, 2017, Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis, J Gerontol A Biol Sci Med Sci, 10.1093/gerona/glx234 · DOI · Paper page
- Espeland, 2017, Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment, Neurology, 88, 2026, 10.1212/WNL.0000000000003955 · DOI · Paper page
- Katan, 1986, Apolipoprotein E isoforms, serum cholesterol, and cancer, Lancet, 1, 507, 10.1016/S0140-6736(86)92972-7 · DOI · Paper page
- Cataldo, 2010, Cigarette smoking is a risk factor for Alzheimer’s disease: an analysis controlling for tobacco industry affiliation, J Alzheimers Dis, 19, 465, 10.3233/JAD-2010-1240 · DOI · Paper page
- Thomas, 2010, Gene–environment-wide association studies: emerging approaches, Nat Rev Genet, 11, 259, 10.1038/nrg2764 · DOI · Paper page
- Carroll, 2017, Another Alzheimer’s drug flops in pivotal clinical trial, Science, 10.1126/science.aal0759 · DOI
- Gold, 2017, Phase II clinical trials of anti-amyloid beta antibodies: when is enough, enough?, Alzheimers Dement (N Y), 3, 402, 10.1016/j.trci.2017.04.005 · DOI · Paper page
- Giacobini, 2013, Alzheimer disease therapy – moving from amyloid-beta to tau, Nat Rev Neurol, 9, 677, 10.1038/nrneurol.2013.223 · DOI · Paper page
- Reiman, 2016, CAP – advancing the evaluation of preclinical Alzheimer disease treatments, Nat Rev Neurol, 12, 56, 10.1038/nrneurol.2015.177 · DOI · Paper page
- Reitz, 2016, Toward precision medicine in Alzheimer’s disease, Ann Transl Med, 4, 107, 10.21037/atm.2016.03.05 · DOI · Paper page
- Blennow, 2015, Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease, Alzheimers Dement, 11, 58, 10.1016/j.jalz.2014.02.004 · DOI · Paper page
- Mittal, 2017, beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease, Science, 357, 891, 10.1126/science.aaf3934 · DOI · Paper page
- Phillips, 2016, Only a click away – DTC genetics for ancestry, health, love … and more: a view of the business and regulatory landscape, Appl Transl Genom, 8, 16, 10.1016/j.atg.2016.01.001 · DOI · Paper page
- Defesche, 2017, Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia, J Clin Lipidol, 11, 1338, 10.1016/j.jacl.2017.08.016 · DOI · Paper page
- Crane, 2017, Alzheimer’s disease sequencing project discovery and replication criteria for cases and controls: data from a community-based prospective cohort study with autopsy follow-up, Alzheimers Dement, 13, 1410, 10.1016/j.jalz.2017.09.010 · DOI
- Mapes, 2017, How should clinicians counsel a woman with a strong family history of early-onset Alzheimer’s disease about her pregnancy?, AMA J Ethics, 19, 663, 10.1001/journalofethics.2017.19.7.ecas4-1707 · DOI
- Caulfield, 2013, Harm, hype and evidence: Elsi research and policy guidance, Genome Med, 5, 21, 10.1186/gm425 · DOI
Cited by
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N. M., Scheltens, P., van der Flier, W. M., Huisman, M., Reinders, M. J. T., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01018-7 · Cited by 67
“4 An accurate mapping of the genetic risk of AD conferred by specific molecular pathways may lead to a greater 80 comprehension of individual AD subtypes and might represent a first important step for the development of targeted 81 intervention strategies and personalized medicine.[31] Here, we propose a novel integra…”
BackgroundBracher-Smith, M., Leonenko, G., Baker, E., Crawford, K., Graham, A. C., Salih, D. A., Howell, B. W., Hardy, J., & Escott-Price, V. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.009 · Cited by 31
Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model
Wu, J., Chen, Y., Wang, P., Caselli, R. J., Thompson, P. M., Wang, J., & Wang, Y. (2022) · Frontiers in Radiology · doi:10.3389/fradi.2021.777030 · Cited by 17
Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13
Metadata
- Authors
- Freudenberg-Hua, Y., Li, W., & Davies, P.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2018-04-24
- Volume
- 5
- Pages
- 108-108
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2802923338
- Cited by
- 74
- References
- 82
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Institutes of Health (1K08AG054727-01A1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.